FIELD: biotechnology.
SUBSTANCE: present invention relates to the field and can be used in medicine. Invention discloses combinations containing leptin receptor antagonists, GDF8 and activin A, as well as methods of using them. There are also provided methods of treating malnutrition, cachexia and other conditions characterized by malnutrition and weight loss.
EFFECT: such compositions are effective, for example, to provide an increase in the mass of non-adipose body tissues at least partially due to the fat mass.
26 cl, 4 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGONISTIC ANTIBODY TO LEPTIN RECEPTOR FOR USE IN TREATMENT OF METABOLISM DISORDERS OR HYPOLEPTINEMIA | 2019 |
|
RU2812670C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE ERYTHROCYTE COUNT | 2020 |
|
RU2814047C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
